Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Buy Of Lilly’s COVID-19 Therapy Now Turns On FDA's Manufacturing Quality Assessment

Oct 29 2020

• By Bowman Cox

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease — Lilly covid antibodies sold if authorized

Related Content

COVID-19 Vaccines: Advisory Committee Picks Apart US FDA Guidance On Efficacy Endpoints

Oct 23 2020

Lilly's US Bamlanivimab Contract Raises Difficult Allocation Considerations

Oct 28 2020

Plasma Authorization Raises Fears Of Politically-Influenced COVID-19 Vaccine Decisions, Compromised FDA

Aug 25 2020

Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

Aug 20 2020

CGMP Requirements Apply To Remdesivir In COVID-19 Emergency – But Not To Chloroquine Or HCQ

May 07 2020

Related Companies

Eli Lilly and Company

Regeneron Pharmaceuticals, Inc.

Additional Topics

United States Coronavirus COVID-19 Manufacturing Quality Infectious Diseases BioPharmaceutical

More from Manufacturing

More from Compliance

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window